New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2014
08:08 EDTKOCoca-Cola to acquire Appletiser brands from SABMiller for $260M
As part of the transaction to form Coca-Cola Beverages Africa, Coca-Cola (KO) will acquire SABMiller's (SBMRY) Appletiser brands on a worldwide basis, and acquire or be licensed rights to a further 19 non-alcoholic ready-to-drink brands in Africa and in Latin America, for an approximate cash consideration of $260M. SABMiller will retain ownership of its non-alcoholic malt beverages in Africa and Latin America and will retain its Coca-Cola franchises in El Salvador and Honduras.
08:07 EDTKOCoca-Cola, SABMiller to form Coca-Cola Beverages Africa
Subscribe for More Information
November 26, 2014
10:21 EDTJNJJohnson & Johnson Zytiga lost share for second month, says Wells Fargo
Subscribe for More Information
November 24, 2014
11:25 EDTJNJStryker, Smith & Nephew rise after reports of renewed bid
Subscribe for More Information
09:26 EDTJNJFDA updates warning on laparoscopic power morcellators to treat uterine fibroids
The FDA announced it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April, the FDA warns against using laparoscopic power morcellators in the removal of the uterus or fibroids in the vast majority of women. In an Immediately in Effect guidance, the FDA is also recommending that manufacturers of laparoscopic power morcellators include in their product labeling specific safety statements in the form of a boxed warning and two contraindications. Johnson & Johnson (JNJ), the largest manufacturer of morcellators, stopped selling the gynecological surgical tool in April and in August told customers to return any devices in their inventory. Intuitive Surgical's (ISRG) da Vinci surgical system can be used with tissue morcellators in such surgical procedures.
November 20, 2014
11:58 EDTKOKeurig Green Mountain sinks after Q1 outlook disappoints, CFO reports departure
Subscribe for More Information
November 19, 2014
18:11 EDTKOKeurig Green Mountain says 2.0 brewer introduced on time with retailer support
Says retailers aggressively ordered portion packs in Q4. Says brewer inventory levels "healthy" for upcoming holiday season. Says will run local, national TV ads during the holidays. Says Canadian business down for FY14. Says will offer 70 brands for brewers by March, 2015. Says on track to launch Keurig Cold in fall of 2015. Says working closely with Coca-Cola (KO) on cold brewing system. Says in FY15, expects growth in portion pack sales to accelerate as the year progresses. Says over 90% locked for coffee costs for FY15, but higher than FY14. Says coffee costs will be a headwind in 2Q15. Says expects some gross margin pressure in Q1. Says continues to expect long-term annual revenue, EPS growth in mid-teens. Comments from company's Q4 earnings conference call.
14:08 EDTKOEarnings Preview: Keurig Green Mountain sees FY14 EPS $3.71-$3.78
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
08:54 EDTNTRSExecutives' Club of Chicago to hold a meeting
CIO Murray of Northern Trust and Managing Director Larson of Accenture participate in a speech entitled, "Shifting Gears: Transforming to a Digital Enterprise in a meeting being held in Chicago on November 19 at 6 pm.
08:15 EDTKOGreat Lakes Coca-Cola Distribution signs definitive agreement with Coca-Cola
Subscribe for More Information
06:30 EDTJNJJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
16:00 EDTKOOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
14:20 EDTKOCoca-Cola rumored to be in sights of 3G Capital, Forbes contributor reports
Investment firm 3G Capital is in advanced talks for a new fund targeted at the food and beverage industry, according to Veja magazine, reported a contributor to Forbes. The new fund could be used to acquire a significant stake in Coca-Cola or possibly even be used to orchestrate a takeover of the beverage giant, according to Veja columnist Geraldo Samor, the Forbes report said. Shares of Coca-Cola have moved into positive territory and are up 0.5% in afternoon trading following the circulation of the Forbes article. Reference Link
November 17, 2014
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
08:47 EDTSCHWCharles Schwab reports October net new assets $7.9B
The Charles Schwab Corporation released its Monthly Activity Report. Company highlights for the month of October 2014 include: Net new assets brought to the company by new and existing clients in October 2014 totaled $7.9B. Total client assets were $2.44T as of month-end October, up 12% from October 2013 and up 2% compared to September 2014. Average interest-earning assets on the company’s balance sheet were a record $141.5B as of month-end October, up 5% from October 2013 and up 1% compared to September 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use